Drug intelligence / Profile preview

TRG-001

Development stage: Preclinical
Lead developer: Cothera Bioscience
Modality: Small Molecules

Overview

TRG-001 is a novel cytotoxic agent developed by Tragara Pharmaceuticals. It functions as a microtubule-targeting agent, designed for the treatment of multiple myeloma. The Multiple Myeloma Research Foundation (MMRF) provided a multi-year research grant to Tragara Pharmaceuticals to support the early-stage development of TRG-001.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on TRG-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRG-001.

Explore the full profile